Статья

Allogeneic hematopoietic stem cell transplantation in leukocyte adhesion deficiency type I and III

S. Bakhtiar, E. Salzmann-Manrique, H. Blok, D. Eikema, S. Hazelaar, M. Ayas, A. Toren, G. Goldstein, D. Moshous, F. Locatelli, P. Merli, G. Michel, G. Ozturk, A. Schulz, C. Heilmann, M. Ifversen, R. Wynn, O. Aleinikova, Y. Bertrand, A. Tbakhi, P. Veys, M. Karakukcu, A. Kupesiz, A. Ghavamzadeh, R. Handgretinger, E. Unal, A. Perez-Martinez, M. Gokce, F. Porta, T. Aksu, G. Karasu, I. Badell, P. Ljungman, E. Skorobogatova, A. Yesilipek, T. Zuckerman, R. Bredius, P. Stepensky, B. Shadur, M. Slatter, A. Gennery, M. Albert, P. Bader, A. Lankester,
2021

Type I and III leukocyte adhesion deficiencies (LADs) are primary immunodeficiency disorders resulting in early death due to infections and additional bleeding tendency in LAD-III. The curative treatment of LAD-I and LAD-III is allogeneic hematopoietic stem cell transplantation (allo-HSCT). In this retrospective multicenter study, data were collected using the European Society for Blood and Marrow Transplantation registry; we analyzed data from 84 LAD patients from 33 centers, all receiving an allo-HSCT from 2007 to 2017. The 3-year overall survival estimate (95% confidence interval [CI]) was 83% (74-92) for the entire cohort: 84% (75-94) and 75% (50-100) for LAD-I and LAD-III, respectively. We observed cumulative incidences (95% CI) of graft failure (GF) at 3 years of 17% (9%-26%) and grade II to IV acute graft-versus-host disease (aGVHD) at 100 days of 24% (15%-34%). The estimate (95% CI) at 3 years for GF- and GVHD-II to IV-free survival as event-free survival (EFS) was 56% (46-69) for the entire cohort; 58% (46-72) and 56% (23-88) for LAD-I and LAD-III, respectively. Grade II to IV acute GVHD was a relevant risk factor for death (hazard ratio 3.6; 95% CI 1.4-9.1; P 5.006). Patients' age at transplant $13 months, transplantation from a nonsibling donor, and any serological cytomegalovirus mismatch in donor-recipient pairs were significantly associated with severe acute GVHD and inferior EFS. The choice of busulfan- or treosulfan-based conditioning, type of GVHD prophylaxis, and serotherapy did not impact overall survival, EFS, or aGVHD. An intrinsic inflammatory component of LAD may contribute to inflammatory complications during allo-HSCT, thus providing the rationale for considering anti-inflammatory therapy pretreatment.

Цитирование

Похожие публикации

Документы

Источник

Версии

  • 1. Version of Record от 2021-01-12

Метаданные

Об авторах
  • S. Bakhtiar
    Universitätsklinikum Frankfurt
  • E. Salzmann-Manrique
    Universitätsklinikum Frankfurt
  • H. Blok
    Leiden University Medical Center - LUMC
  • D. Eikema
    Leiden University Medical Center - LUMC
  • S. Hazelaar
    Leiden University Medical Center - LUMC
  • M. Ayas
    King Faisal Specialist Hospital and Research Centre
  • A. Toren
    Chaim Sheba Medical Center Israel
  • G. Goldstein
    Chaim Sheba Medical Center Israel
  • D. Moshous
    Hôpital Necker Enfants Malades, l'Institut des Maladies Génétiques Imagine, Université de Paris
  • F. Locatelli
    Sapienza Università di Roma
  • P. Merli
    Sapienza Università di Roma
  • G. Michel
    Hopital La Timone
  • G. Ozturk
    Acibadem Mehmet Ali Aydinlar Universitesi
  • A. Schulz
    Universitätsklinikum Ulm
  • C. Heilmann
    Rigshospitalet
  • M. Ifversen
    Rigshospitalet
  • R. Wynn
    Royal Manchester Children's Hospital
  • O. Aleinikova
    Belarussian Centre for Paediatric Oncology and Hematology
  • Y. Bertrand
    CHU de Lyon
  • A. Tbakhi
    King Hussein Cancer Centre
  • P. Veys
    University College London
  • M. Karakukcu
    Erciyes Üniversitesi
  • A. Kupesiz
    Akdeniz Üniversitesi
  • A. Ghavamzadeh
    Shariati Hospital
  • R. Handgretinger
    Universitätsklinikum Tübingen Medizinische Fakultät
  • E. Unal
    Ankara Üniversitesi
  • A. Perez-Martinez
    Hospital Universitario La Paz
  • M. Gokce
    Yeni Yüzyıl Üniversitesi
  • F. Porta
    Ospedale dei Bambini
  • T. Aksu
    Ankara Children's Hematology Oncology Training and Research Hospital
  • G. Karasu
    Medical Park Goztepe Hospital
  • I. Badell
    Hospital de La Santa Creu I Sant Pau
  • P. Ljungman
    Karolinska University Hospital
  • E. Skorobogatova
    Russian Children's Hospital
  • A. Yesilipek
    Medical Park Antalya Hospital
  • T. Zuckerman
    Rambam Health Care Campus Israel
  • R. Bredius
    Leiden University Medical Center - LUMC
  • P. Stepensky
    Hadassah University Medical Centre
  • B. Shadur
    Hadassah University Medical Centre
  • M. Slatter
    Newcastle University
  • A. Gennery
    Newcastle University
  • M. Albert
    Klinikum der Universität München
  • P. Bader
    Universitätsklinikum Frankfurt
  • A. Lankester
    Leiden University Medical Center - LUMC
Название журнала
  • Blood Advances
Том
  • 5
Выпуск
  • 1
Страницы
  • 262-273
Финансирующая организация
  • Goethe-Universität Frankfurt am Main
Номер гранта
  • undefined
Тип документа
  • journal article
Тип лицензии Creative Commons
  • CC BY
Правовой статус документа
  • Свободная лицензия
Источник
  • scopus